Dysregulation of mTOR by tau in Alzheimer's disease

George S Bloom1,2,3, Andrés Norambuena1

  • 1Department of Biology, University of Virginia, Charlottesville, Virginia, USA.

PubMed

Insights

Aberrant tau phosphorylation, triggered by amyloid-β oligomers, causes neurons to re-enter the cell cycle and die, inhibiting nutrient-induced mitochondrial activation in Alzheimer's disease (AD). This tau-driven neurodegeneration impacts key cellular processes.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Biochemistry

Background:

  • Tau protein is primarily found in neurons and is a key component of neurofibrillary tangles (NFTs) in Alzheimer's disease (AD).
  • Dysregulation of the mTOR pathway is implicated in various cellular processes and diseases.
  • Amyloid-β oligomers (AβOs) are known contributors to AD pathogenesis.

Purpose of the Study:

  • To investigate the role of tau in the dysregulation of mTOR signaling in Alzheimer's disease.
  • To elucidate the complex mechanisms of tau-induced neurodegeneration beyond NFTs.
  • To explore the impact of tau on nutrient-induced mitochondrial activation (NiMA).

Main Methods:

  • Review of existing research on tau, mTOR, and AD.
  • Analysis of signaling networks involving tau phosphorylation and mTOR.
  • Experimental studies on cultured neurons exposed to AβOs.

Main Results:

  • Aberrant tau phosphorylation, induced by AβOs, triggers post-mitotic neurons to re-enter the cell cycle, leading to eventual cell death.
  • This tau-mediated signaling network inhibits nutrient-induced mitochondrial activation (NiMA).
  • Tau-dependent cell cycle re-entry and NiMA inhibition occur rapidly (within hours) upon AβO exposure in neurons.

Conclusions:

  • Tau plays a critical role in AD pathogenesis by dysregulating mTOR signaling, leading to neurodegeneration.
  • The findings suggest that tau-induced cell cycle re-entry and NiMA inhibition are early and fundamental events in AD.
  • Understanding these tau-driven mechanisms offers potential new therapeutic targets for Alzheimer's disease.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212